Another enterprise in Tianfu Life Science Park completed Series A funding.

          Chengdu Aoda Biotechnology Co., Ltd., a developer of long-acting polypeptide drugs located in Tianfu Life Science Park, has reportedly completed Series A funding.

       Investors in this round included Jiaxing Renxi Medical Industry Equity Investment Partnership (subordinate to Renxi Science and Technology Innovation Industry Investment Private Equity Fund) and Chengdu Songhe Yijian Venture Capital Partnership (subordinate to Green Pine Capital Partners).

Chengdu Aoda Biotechnology Co., Ltd.

        Chengdu Aoda Biotechnology Co., Ltd. was registered and established in the Chengdu Hi-tech Industrial Development Zone in March 2017. Its business scope covers biomedicine, pharmaceutical technology development, technical consultation, and technology transfer. Aoda focuses on the R&D of long-acting drugs for type II diabetes, pan-coronavirus membrane fusion inhibitors, polypeptide vaccines for multiple myeloma and neuroprotective agents for stroke recovery. Aoda has applied for over 50 compound invention patents and has been granted 14 invention patents and 22 utility model patents. Furthermore, it has obtained 2 implied licenses for clinical trials.

          Exd391209 and LLT311202, both GLP-1 agonists currently under development for the treatment of type 2 diabetes, have been approved for clinical trials. In 2021, Aoda was recognized as a High-Tech Enterprise and Gazelle Enterprise; in 2022, it earned the designation of Specialized, Sophisticated, Distinctive and Innovative SME in Sichuan Province.

R&D Direction

       Polypeptide drugs: They are easy to synthesize, optimize, modify and combine, enabling rapid assessments of their medicinal value; compared to macromolecular drugs, the chemical synthesis technology for polypeptide drugs is well-established; compared to small molecule drugs, polypeptide drugs produce better effects, stronger specificity, stronger selectivity and fewer side effects with lower dosage.

       Long-acting polypeptide drugs: Their half-lives can be prolonged by dozens of times through modifications; their dosing frequency can be reduced from 1–3 times a day to once a week or once every 2 weeks, greatly increasing patient compliance.

     Targeted polypeptide drugs: Virus fusion inhibitors, targeted anti-tumor polypeptides and antibacterial polypeptides.

        The investors said, "This round of investment is not only an injection of funds, but also a high recognition of Aoda's innovation capabilities and market potential. Aoda is expected to spearhead a groundbreaking revolution in the biomedical industry, paving the way for a healthier future with more outstanding achievements."